QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines

Test your understanding of the concepts covered by Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which approach is most appropriate when preparing an MAH response to an Article 20 safety concern?

Present only evidence supporting maintenance of the current label Provide a balanced evidence package covering supporting and challenging evidence, uncertainties and regulatory implications Focus primarily on the number of spontaneous reports Avoid discussing alternative explanations because they may weaken the company's position

Question 2 of 10 Which finding would most clearly indicate a broader pharmacovigilance system weakness revealed by an Article 20 procedure?

The procedure required review of clinical evidence The MAH found that safety interpretations were inconsistent across functions and could not be readily reconciled PRAC requested additional information The Commission adopted a decision after the CHMP opinion

Question 3 of 10 Which document has the legally operative Union effect in the Article 20 decision chain?

The MAH's response document The PRAC recommendation The CHMP opinion The European Commission decision

Question 4 of 10 What is the most accurate description of CHMP's role in the Article 20 pathway?

CHMP replaces PRAC and repeats the entire pharmacovigilance investigation independently CHMP considers the PRAC recommendation and adopts the relevant opinion within the centralised framework CHMP directly imposes binding changes on all MAHs CHMP formally initiates the Article 20 procedure

Question 5 of 10 Why is authorisation status a key factor when selecting a Union pharmacovigilance procedure?

It determines whether the safety issue can be assessed medically It determines which legal and procedural framework may apply to the affected products It determines whether the MAH must submit individual case reports It determines whether PRAC is permitted to review the evidence

Question 6 of 10 What is the central question in the benefit-risk assessment during an Article 20 procedure?

Whether the medicine has any risk at all Whether every reported event is causally related to treatment Whether the benefit-risk balance remains favourable under the authorised or proposed conditions of use Whether the company can avoid changing the product information

Question 7 of 10 Which interpretation of epidemiological evidence is most consistent with the article?

Statistical significance automatically proves causality A non-significant result automatically proves absence of risk Study design, bias, confounding, uncertainty and the totality of evidence must be considered Epidemiological studies should replace individual case assessment

Question 8 of 10 How should an MAH express scientific disagreement with an emerging PRAC interpretation?

State that the committee is incorrect without discussing evidence Identify the precise point of disagreement, present supporting evidence, acknowledge contrary evidence and explain the regulatory consequence Withhold all disagreement until after the Commission decision Replace the scientific discussion with commercial arguments

Question 9 of 10 Which statement best describes the QPPV's responsibility after an Article 20 outcome?

The QPPV must personally perform every implementation task The QPPV's involvement ends when the Commission decision is published The QPPV should oversee whether the pharmacovigilance consequences are appropriately incorporated into the company's system The QPPV is responsible for adopting the Commission decision

Question 10 of 10 A company argues that a previous internal assessment found no need for regulatory action, so the Article 20 concern must be unfounded. What is the most appropriate professional response?

Accept the earlier conclusion as permanently determinative Reject all previous assessments as irrelevant Compare the current and historical evidence bases and explain what has changed, if anything Use only the newest individual case to resolve the disagreement

QPPV.com

Knowledge Assessment: Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines

Cookie Settings